Who are DAS181 COVID-19's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/das181-covid-19.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

DAS181 COVID-19 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DAS181 COVID-19 (DAS181 COVID-19) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE2 receptor decoy / recombinant fusion protein. Area: Infectious Disease / Virology.

phase 3 ACE2 receptor decoy / recombinant fusion protein SARS-CoV-2 spike protein (via ACE2 binding domain) Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

DAS181 COVID-19 (DAS181 COVID-19) — Ansun Biopharma, Inc.. DAS181 is a recombinant fusion protein that blocks SARS-CoV-2 entry into human cells by targeting the ACE2 receptor on the cell surface.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DAS181 COVID-19 TARGET	DAS181 COVID-19	Ansun Biopharma, Inc.	phase 3	ACE2 receptor decoy / recombinant fusion protein	SARS-CoV-2 spike protein (via ACE2 binding domain)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE2 receptor decoy / recombinant fusion protein class)

Ansun Biopharma, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DAS181 COVID-19 — Competitive Intelligence Brief. https://druglandscape.com/ci/das181-covid-19. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing